Compare · IMMU vs LNTH
IMMU vs LNTH
Side-by-side comparison of Immunomedics, Inc. (IMMU) and Lantheus Holdings Inc. (LNTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMMU and LNTH operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH carries a market cap of $6.56B.
- LNTH has hit the wire 11 times in the past 4 weeks while IMMU has been quiet.
- LNTH has more recent analyst coverage (17 ratings vs 0 for IMMU).
- Company
- Immunomedics, Inc.
- Lantheus Holdings Inc.
- Price
- -
- $100.42-0.53%
- Market cap
- -
- $6.56B
- 1M return
- -
- -0.54%
- 1Y return
- -
- +87.14%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2015
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 17
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Latest IMMU
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- NorthStar Appoints Peter Pfreundschuh to Board of Managers
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- SEC Form SC 13G/A filed
Latest LNTH
- Large owner Lantheus Alpha Therapy, Llc sold $776,947 worth of shares (247,932 units at $3.13) (SEC Form 4)
- SEC Form DEFM14A filed by Lantheus Holdings Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Lantheus Holdings Inc.
- Large owner Lantheus Alpha Therapy, Llc sold $131,219 worth of shares (42,129 units at $3.11) (SEC Form 4)
- Large owner Lantheus Holdings, Inc. sold $111,574 worth of shares (35,769 units at $3.12) (SEC Form 4)
- Large owner Lantheus Holdings, Inc. sold $245,610 worth of shares (78,145 units at $3.14) (SEC Form 4)
- CFO and Treasurer Marshall Robert J. Jr. covered exercise/tax liability with 721 shares, decreasing direct ownership by 0.59% to 122,071 units (SEC Form 4)
- SEC Form S-8 filed by Lantheus Holdings Inc.
- SEC Form PREM14A filed by Lantheus Holdings Inc.
- Chief Accounting Officer Brown Kimberly covered exercise/tax liability with 463 shares, decreasing direct ownership by 3% to 13,263 units (SEC Form 4)